Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of PF708 and Forteo in Healthy Adults
NCT02656810Phase 1Completed
- Sponsor
- Pfenex Inc.
- Start
- Dec 2015
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of teriparatide in osteoporosis (2 arms), sponsored by Pfenex Inc. Primary endpoints: Serum area-under-the-curve at 24 hours and Serum maximum concentration at 24 hours. Started Dec 2015; status: completed.
02
Drugs
teriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT02656810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02656810.